Literature DB >> 35241463

Medical expenditure and its influencing factors of patients with hypertension in Shanxi Province, China: a study based on 'System of Health Accounts 2011' and multiple-layer perceptron neural network.

Guojie Liu1, Quan Fang2, Xinyu Ji3, Jing OuYang4, Yalan Zhu2, Leying Wang5, Xin Wang6,7.   

Abstract

OBJECTIVES: To study the medical expenditure and influencing factors of patients with hypertension in Shanxi Province, China.
DESIGN: A cross-sectional study.
SETTING: 1088 medical institutions, including general hospitals, traditional Chinese medicine hospitals, special hospitals, basic medical institutions and public health institutions. PARTICIPANTS: 180 441 hypertensive outpatients and 14 763 inpatients from 1 January to 31 December 2017. PRIMARY AND SECONDARY OUTCOME MEASURES: Curative care expenditure for hypertension (CCEht) was measured based on System of Health Accounts 2011. Influenced factors were analysed by univariate analysis and multiple layer perceptron neural network.
RESULTS: In 2017, CCEht was US$307.71 million, accounting for 3.63% of total CCE and 0.14% of gross domestic product (GDP) in Shanxi Province of China. CCE of hypertensive outpatients (CCEht-out) and inpatients (CCEht-in) accounted for 44.49% and 55.51% of CCEht. Drug fee accounted for 81.55% of CCEht-out and 22.50% of CCEht-in, respectively. The top three influencing factors were drug fee, surgical fee and hospitalisation days for inpatients, and drug fee, examination fee and test fee for outpatients.
CONCLUSIONS: The medical expenditure of hypertension is still heavy for individuals and society. The diagnosis and treatment capacities of primary healthcare system has been enhanced. New rural cooperation medical insurance and urban employee basic medical insurance have a trend of overusing, and the burden of family healthcare expenditure is still heavy. To ease the economic burden of patients with hypertension and improve the efficiency of social resources utilisation, policymakers should pay more attention to key groups, further increase support for primary healthcare system, standardise the treatment and reimbursement of hypertension and incline the reimbursement policy to outpatient service. © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  health economics; health policy; health services administration & management; hypertension

Mesh:

Year:  2022        PMID: 35241463      PMCID: PMC8895933          DOI: 10.1136/bmjopen-2020-048396

Source DB:  PubMed          Journal:  BMJ Open        ISSN: 2044-6055            Impact factor:   2.692


  23 in total

Review 1.  Future of Hypertension.

Authors:  Victor J Dzau; Celynne A Balatbat
Journal:  Hypertension       Date:  2019-07-29       Impact factor: 10.190

2.  Discordance in national estimates of hypertension among young adults.

Authors:  Quynh C Nguyen; Joyce W Tabor; Pamela P Entzel; Yan Lau; Chirayath Suchindran; Jon M Hussey; Carolyn T Halpern; Kathleen Mullan Harris; Eric A Whitsel
Journal:  Epidemiology       Date:  2011-07       Impact factor: 4.822

Review 3.  Gender Differences in Epidemiology, Pathophysiology, and Treatment of Hypertension.

Authors:  Paolo Di Giosia; Paolo Giorgini; Cosimo Andrea Stamerra; Marco Petrarca; Claudio Ferri; Amirhossein Sahebkar
Journal:  Curr Atheroscler Rep       Date:  2018-02-14       Impact factor: 5.113

4.  [2010 Chinese guidelines for the management of hypertension].

Authors:  Li-Sheng Liu
Journal:  Zhonghua Xin Xue Guan Bing Za Zhi       Date:  2011-07

5.  Geographical variations in hypertension prevalence, awareness, treatment and control in China: findings from a nationwide and provincially representative survey.

Authors:  Yichong Li; Limin Wang; Xiaoqi Feng; Mei Zhang; Zhengjing Huang; Qian Deng; Maigeng Zhou; Thomas Astell-Burt; Linhong Wang
Journal:  J Hypertens       Date:  2018-01       Impact factor: 4.844

6.  Prevalence, Awareness, Treatment, Control and Risk Factors Associated with Hypertension among Adults in Southern China, 2013.

Authors:  Li Yang; Jing Yan; Xinhua Tang; Xiaoling Xu; Wei Yu; Haibin Wu
Journal:  PLoS One       Date:  2016-01-19       Impact factor: 3.240

7.  Catastrophic healthcare expenditure and its inequality for households with hypertension: evidence from the rural areas of Shaanxi Province in China.

Authors:  Yafei Si; Zhongliang Zhou; Min Su; Meng Ma; Yongjian Xu; Jesse Heitner
Journal:  Int J Equity Health       Date:  2017-07-01

8.  Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants.

Authors: 
Journal:  Lancet       Date:  2021-08-24       Impact factor: 79.321

9.  Will the zero-margin drug policy reduce the economic burden of stroke patients in China?

Authors:  Quan Fang; Degao Shang; Yunxia Zhang; Xinli Geng; Fang Liu; Qin Zhang; Xin Wang
Journal:  J Glob Health       Date:  2021-09-30       Impact factor: 4.413

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.